Moderna (NASDAQ: MRNA) reported quarterly losses of $(2.91) per share which missed the analyst consensus estimate of $(2.62) by 11.07 percent. This is a 629.09 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $966.00 million which beat the analyst consensus estimate of $942.84 million by 2.46 percent. This is a 65.64 percent decrease over sales of $2.81 billion the same period last year.